858 Therapeutics Logo

Pipeline

At 858 Therapeutics, we are advancing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. Our programs are focused on important nodes in cancer biology, including DNA damage repair, innate immunity, and RNA epigenetics. We leverage our deep expertise in structure-based drug discovery and translational research to develop differentiated drug candidates.

TargetIndicationDiscoveryPreclinicalIND-enablingClinicalRights
PARGSolid tumors858 Therapeutics Logo
QPCT/LNeurodegeneration858 Therapeutics Logo
METTL3Solid tumors858 Therapeutics Logo
ADAR1Solid tumors858 Therapeutics Logo

Target:

PARG

Indication:

Solid tumors

Discovery Preclinical IND-enabling Clinical

Rights:

858 Therapeutics Logo

Target:

QPCT/L

Indication:

Neurodegeneration

Discovery Preclinical IND-enabling Clinical

Rights:

858 Therapeutics Logo

Target:

METTL3

Indication:

Solid tumors

Discovery Preclinical IND-enabling Clinical

Rights:

858 Therapeutics Logo

Target:

ADAR1

Indication:

Solid tumors

Discovery Preclinical IND-enabling Clinical

Rights:

858 Therapeutics Logo

To learn more about partnering or licensing opportunities, please contact bd@8five8tx.com